271 related articles for article (PubMed ID: 26463521)
1. NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer.
Adkins CE; Nounou MI; Hye T; Mohammad AS; Terrell-Hall T; Mohan NK; Eldon MA; Hoch U; Lockman PR
BMC Cancer; 2015 Oct; 15():685. PubMed ID: 26463521
[TBL] [Abstract][Full Text] [Related]
2. Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer.
Mohammad AS; Griffith JI; Adkins CE; Shah N; Sechrest E; Dolan EL; Terrell-Hall TB; Hendriks BS; Lee H; Lockman PR
Pharm Res; 2018 Jan; 35(2):31. PubMed ID: 29368289
[TBL] [Abstract][Full Text] [Related]
3. SN38 polymeric nanoparticles: in vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecan.
Sepehri N; Rouhani H; Tavassolian F; Montazeri H; Khoshayand MR; Ghahremani MH; Ostad SN; Atyabi F; Dinarvand R
Int J Pharm; 2014 Aug; 471(1-2):485-97. PubMed ID: 24879937
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma.
Iyer R; Croucher JL; Chorny M; Mangino JL; Alferiev IS; Levy RJ; Kolla V; Brodeur GM
Cancer Lett; 2015 May; 360(2):205-12. PubMed ID: 25684664
[TBL] [Abstract][Full Text] [Related]
5. DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies.
Meyer-Losic F; Nicolazzi C; Quinonero J; Ribes F; Michel M; Dubois V; de Coupade C; Boukaissi M; Chéné AS; Tranchant I; Arranz V; Zoubaa I; Fruchart JS; Ravel D; Kearsey J
Clin Cancer Res; 2008 Apr; 14(7):2145-53. PubMed ID: 18381956
[TBL] [Abstract][Full Text] [Related]
6. Vinorelbine Delivery and Efficacy in the MDA-MB-231BR Preclinical Model of Brain Metastases of Breast Cancer.
Samala R; Thorsheim HR; Goda S; Taskar K; Gril B; Steeg PS; Smith QR
Pharm Res; 2016 Dec; 33(12):2904-2919. PubMed ID: 27541873
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticles Containing a Combination of a Drug and an Antibody for the Treatment of Breast Cancer Brain Metastases.
Wyatt EA; Davis ME
Mol Pharm; 2020 Feb; 17(2):717-721. PubMed ID: 31916770
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, characterization, and antitumor evaluation of the albumin-SN38 conjugate.
Yao Y; Su X; Xie Y; Wang Y; Kang T; Gou L; Yi C; Yang J
Anticancer Drugs; 2013 Mar; 24(3):270-7. PubMed ID: 23233044
[TBL] [Abstract][Full Text] [Related]
9. PEG-coated irinotecan cationic liposomes improve the therapeutic efficacy of breast cancer in animals.
Zhang L; Cao DY; Wang J; Xiang B; Dun JN; Fang Y; Xue GQ
Eur Rev Med Pharmacol Sci; 2013 Dec; 17(24):3347-61. PubMed ID: 24379067
[TBL] [Abstract][Full Text] [Related]
10. Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.
Hoch U; Staschen CM; Johnson RK; Eldon MA
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1125-37. PubMed ID: 25228368
[TBL] [Abstract][Full Text] [Related]
11. [Irinotecan pharmacokinetics].
Chabot GG; Robert J; Lokiec F; Canal P
Bull Cancer; 1998 Dec; Spec No():11-20. PubMed ID: 9932079
[TBL] [Abstract][Full Text] [Related]
12. Single protein encapsulated SN38 for tumor-targeting treatment.
Yu C; Huang F; Wang K; Liu M; Chow WA; Ling X; Li F; Causey JL; Huang X; Cook-Wiens G; Cui X
J Transl Med; 2023 Dec; 21(1):897. PubMed ID: 38072965
[TBL] [Abstract][Full Text] [Related]
13. Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration.
Sy SK; Sweeney TD; Ji C; Hoch U; Eldon MA
Cancer Chemother Pharmacol; 2017 Jan; 79(1):57-67. PubMed ID: 27904955
[TBL] [Abstract][Full Text] [Related]
14. Iterative and prolonged remission in metastatic breast cancer using pegylated irinotecan: a case report.
Amzerin M; Mokrim M; Errihani H; Piccart MJ
J Med Case Rep; 2015 Feb; 9():5. PubMed ID: 25971303
[TBL] [Abstract][Full Text] [Related]
15. Characterization of passive permeability at the blood-tumor barrier in five preclinical models of brain metastases of breast cancer.
Adkins CE; Mohammad AS; Terrell-Hall TB; Dolan EL; Shah N; Sechrest E; Griffith J; Lockman PR
Clin Exp Metastasis; 2016 Apr; 33(4):373-83. PubMed ID: 26944053
[TBL] [Abstract][Full Text] [Related]
16. Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model.
Verreault M; Strutt D; Masin D; Anantha M; Waterhouse D; Yapp DT; Bally MB
J Control Release; 2012 Feb; 158(1):34-43. PubMed ID: 22001870
[TBL] [Abstract][Full Text] [Related]
17. Novel Hydrophilic Camptothecin Derivatives Conjugated to Branched Glycerol Trimer Suppress Tumor Growth without Causing Diarrhea in Murine Xenograft Models of Human Lung Cancer.
Tsuchihashi Y; Abe S; Miyamoto L; Tsunematsu H; Izumi T; Hatano A; Okuno H; Yamane M; Yasuoka T; Ikeda Y; Tsuchiya K
Mol Pharm; 2020 Apr; 17(4):1049-1058. PubMed ID: 32068412
[TBL] [Abstract][Full Text] [Related]
18. Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation.
Pal A; Khan S; Wang YF; Kamath N; Sarkar AK; Ahmad A; Sheikh S; Ali S; Carbonaro D; Zhang A; Ahmad I
Anticancer Res; 2005; 25(1A):331-41. PubMed ID: 15816556
[TBL] [Abstract][Full Text] [Related]
19. Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.
Wang W; Sivakumar W; Torres S; Jhaveri N; Vaikari VP; Gong A; Howard A; Golden EB; Louie SG; Schönthal AH; Hofman FM; Chen TC
Neurosurg Focus; 2015 Mar; 38(3):E8. PubMed ID: 25727230
[TBL] [Abstract][Full Text] [Related]
20. Effects of quercetin combined with anticancer drugs on metastasis-associated factors of gastric cancer cells: in vitro and in vivo studies.
Lei CS; Hou YC; Pai MH; Lin MT; Yeh SL
J Nutr Biochem; 2018 Jan; 51():105-113. PubMed ID: 29125991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]